Introduction: There is an abundance of accumulating data strongly suggesting there is a key
role for the progesterone receptor in the molecular events effecting the growth or …

Cancer and the fetal-placental semi-allograft share certain characteristics, eg, rapid
proliferation, the capacity to invade normal tissue, and, related to the presence of antigens …

Introduction Patients with various advanced cancers devoid of nuclear progesterone
receptors (nPR) have demonstrated increased quality and length of life when treated with …

The ovarian steroid hormones, estradiol and progesterone, and their nuclear receptors
(estrogen receptor [ER] and progesterone receptor [PR]), are involved in breast cancer …

PIBF was previously identified as a 34 kDa immunomodulatory molecule secreted by
pregnancy lymphocytes and is thought to play a crucial role in preventing rejection of the …

Progesterone and progesterone receptors (PR) have a storied albeit controversial history in
breast cancers. As endocrine therapies for breast cancer progressed through the twentieth …

Progesterone induced blocking factor (PIBF) is a unique protein that is not present in normal
cells, but is found predominantly in rapidly growing cells of the fetal placental unit or cancer …

Citation Szekeres‐Bartho J, Polgar B. PIBF: The Double Edged Sword. Pregnancy and
Tumor. Am J Reprod Immunol 2010; 64: 77–86 Problem The role of progesterone …

Purpose: To determine if an immunomodulatory protein (progesterone induced blocking
factor [PIBF]) that is progesterone induced and found in higher concentration during …

Background: Hormonal therapy using progestins, acting through the progesterone receptor
(PR), is a well-established method to treat uterine endometrial hyperplasia and carcinoma …